Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

115.19 +19.38 (+20.23%)
Streaming Delayed Price Updated: 1:46 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
Via Benzinga
Exposures COVID-19
Nasdaq, R2K Futures Tumble Over 4%, VIX Spikes Over 100%, Bitcoin Plunges Hard As Global Sell-Off Deepens Amid Recession Fears
The stock market is on track to gap-open sharply lower on Monday as negative sentiment seen in the final two sessions of last week has carried over into the new week. The index futures were all sharply... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Navigating 12 Analyst Ratings For BioNTech
Via Benzinga
Evaluating BioNTech: Insights From 12 Financial Analysts
Via Benzinga
Evaluating BioNTech: Insights From 15 Financial Analysts
Via Benzinga
What's Going On With BioNTech (BNTX) Shares?
BioNTech shares are trading lower by 5.3% during Thursday's session. Vaccine stocks are down after Moderna cut its 2024 outlook due to weak EU sales and increased U.S. competition. 
Via Benzinga
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
From BioNTech SE
Via GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
From BioNTech SE
Via GlobeNewswire
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while... 
Via Benzinga
Exposures COVID-19
London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents
Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Court, with potential appeals on the horizon and significant financial stakes... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
3 Nasdaq Stocks to Sell in July Before They Crash & Burn
These are three Nasdaq stocks to sell before their value plunges even further due to broader economic pressures. 
Via InvestorPlace
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
Explore three high-yield dividend stocks that not only offer yields of 3% or more but also boast multiple decades of payout growth. 
Via InvestorPlace
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Exposures Product Safety
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
From BioNTech SE
Via GlobeNewswire
GameStop And First Solar Were Among The 10 Biggest Large Cap Losers Last Week (June 16-June 22): Are These In Your Portfolio?
10 worst-performing large-cap stocks last week: GME, ENPH, ALB, BNTX, ALGN, FLSR, BALL, MBLY, BLD, JBL. Are they in your portfolio? 
Via Benzinga
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech partner MediLink Therapeutics faces a partial clinical hold from the FDA on the Phase 1 trial of BNT326/YL202 for advanced non-small cell lung cancer and HR+/HER2-negative breast cancer. 
Via Benzinga
Exposures Product Safety
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
Via Benzinga
Exposures COVID-19 Product Safety
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
What's Going On With Novavax Stock?
Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.